GSK secures second indication for Votrient in Europe for soft tissue sarcoma
This article was originally published in Scrip
Executive Summary
The European Commission has granted marketing authorisation to GlaxoSmithKline's Votrient (pazopanib) for an additional indication – the treatment of adult patients with certain subtypes of advanced soft tissue sarcoma (aSTS) who have received prior chemotherapy or have progressed within 12 months after (neo) adjuvant therapy.